Medical AI developer Heuron plans to file for a KOSDAQ preliminary listing review later this month, despite facing a capital impairment of KRW 65.7 billion.
The company, which specializes in diagnostic solutions for stroke and neurodegenerative diseases, aims to secure its public market debut following a failed 2020 attempt.
Heuron’s path to the stock exchange is heavily obstructed by its current financial standing. According to an audit report by Daejoo Accounting Corp., the company ended last year in a state of capital impairment with an accumulated deficit reaching KRW 65.7 billion. The audit explicitly flagged “material uncertainty related to going concern,” highlighting that the firm’s current liabilities exceed its current assets by KRW 25.4 billion.
The company reported a net profit of KRW 2.2 billion last year, but this figure does not reflect operational cash flow. Instead, it was driven by KRW 8.3 billion in non-cash derivative valuation gains. Meanwhile, actual revenue performance remains modest, totaling only KRW 351.45 million last year—a decline of more than 60% compared to the previous year. To manage these losses, the company reduced its operating expenses from KRW 8.8 billion to KRW 4.5 billion.
Beyond the balance sheet, Heuron faces challenges in the medical marketplace. Its AI-powered diagnostic suites for stroke and neurodegenerative conditions have struggled to gain widespread clinical traction. The adoption of these tools is often hindered by administrative friction; medical institutions frequently report that the requirement for additional patient consent and complex documentation makes the software difficult to integrate into standard workflows.
Because the AI diagnostic tools are not considered mandatory components of the clinical process, hospitals have shown tepid interest in procurement. This lack of clear commercial demand creates a cycle where the technology, despite its high technical evaluation, struggles to generate the revenue necessary to sustain operations without external capital injections.
Heuron’s IPO bid follows its recent performance in the technology assessment phase. In August, the company received an ‘A’ grade from two separate professional evaluation agencies, a prerequisite for the technology special listing track on the KOSDAQ. This technical validation serves as the cornerstone of their current application.
However, the gap between technical assessment and market success remains wide. The company previously raised KRW 15 billion in a pre-IPO round at a valuation exceeding KRW 200 billion during its 2020 attempt, which ultimately failed to reach the public market.
| Financial Metric | Last Year’s Value |
|---|---|
| Accumulated Deficit | KRW 65.7 Billion |
| Revenue | KRW 351.45 Million |
| Working Capital Gap | KRW 25.4 Billion (Liability excess) |
The upcoming preliminary listing review will determine if Heuron can overcome the “going concern” uncertainty that has clouded its financial statements. The company’s ability to prove that its AI diagnostic tools can transition from a niche, voluntary add-on to a standard clinical requirement will be the primary focus for regulators.
Investors will be watching closely to see if the firm can demonstrate a sustainable path to revenue growth, as the current reliance on non-cash valuation gains is unlikely to satisfy long-term market requirements.
The company plans to submit its formal application to the Korea Exchange before the end of November.
